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Beyond the Human Genome 
On the 10
th anniversary of the announcement of the draft 
sequence of the 3 billion DNA bases in the genome by the 
Human Genome Project, there is still a lack of molecular 
targeted therapies for previously intractable diseases. It has 
become clear that the genomes within and across species are 
too similar to explain the diversity of life and the etiology of 
all diseases, indicating that the underlying DNA sequence is 
only one component of this problem. Coinciding with the 
accomplishment of this impressive feat led by the NIH and 
Celera Genomics, has been the explosion of research defined 
as “epigenetic”. The term epigenetics was first coined in the 
1940s by British embryologist and geneticist Conrad Wad-
dington [1], who was attempting to describe “the interactions 
of genes with their environment, which brings the phenotype 
into being”. Since then, this definition has been refined to 
encompass the study of heritable phenotypic traits that result  
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from modifications to a chromosome that do not alter the 
underlying genetic code [2]. An increasing awareness of the 
importance of the temporal and spatial control over the ex-
pression of genes has elevated the study of epigenetics to a 
torrid pace (Fig. 1). There is even a sequel to the Human 
Genome Project, the International Human Epigenome Pro-
ject (IHEP), which was launched in 2010. The IHEP’s goal 
is to understand the patterns of DNA methylation and post-
translational histone modifications that ultimately control 
access of specific genes to transcriptional machinery.  
Epigenetic Therapies Already in the Clinic 
  The potential for new classes of molecular targeted epi-
genetic therapies has begun to be realized with FDA-
approved inhibitors of histone deacetylases (HDACs) (Vori-
nostast and Romidepsin) and DNA methyltransferases 
(DNMTs) (5-azacytidine and 5-aza-2’-deoxycytidine). How-
ever, these agents were discovered based on observation of 
cell phenotypes and the biochemical targets were discovered 
several years later. Suberoylanilide hydroxamic acid (SAHA, 
Vorinostat; approved 2006), the first generation clinical 
















Fig. (1). Epigenetic Research on a Steep Ascent. The search term “epigenetic” was queried by year using the U.S. National Library of 
Medicine Pubmed search engine. *The number of publications for 2011 is an estimate based on the current pace of publications through Feb-
ruary 15
th, 2011. Editorial  Current Chemical Genomics, 2011, Volume 5    49 
notypic screens to be a potent differentiating agent whose 
molecular targets, the HDACs, were identified shortly there-
after [3-5]. Similarly, the azacytidines (5-azacytidine, 
Vidaza; approved 2004 and 5-aza-2’-deoxycytidine, Daco-
gen; approved 2006) were noted to have anti-proliferative 
effects in vitro on cancer cells in 1964, and the molecular 
targets, DNA methyltransferases, were determined only 15 
years later [6, 7]. These discoveries and their subsequent 
development into therapeutic agents indicate the potential of 
epigenetic therapies. As a result target-centric, bottom-up 
approaches to epigenetic drug discovery have rapidly inten-
sified across both industry and academia. Epigenetic targets 
are now ubiquitous in drug discovery pipelines and there are 
now multiple biotechnology companies dedicated to pursu-
ing epigenetic therapies, as highlighted in a recent review by 
Mack [8]. 
Histone Methylation: The Next Epigenetic Therapy? 
  An extensive literature search reveals at least 232 en-
zymes that are proven or postulated to add or remove histone 
post-translational modifications (Fig. 2). Given that histone 
acetylation and DNA methylation have already been ex-
ploited with approved therapeutics, this issue of Current 
Chemical Genomics focuses on histone lysine methylation, 
which is emerging as an attractive target for drug discovery. 
Amongst histone-modifying enzymes, the lysine and argin-
ine methyltransferases (KMTs and RMTs), and lysine de-
methylases (KDMs) comprise more than half of the total 
number, yet there are no inhibitors of these enzymes in clini-
cal studies. Furthermore, a growing body of evidence sug-
gests that genetically driven alteration of their enzymatic 
activities and specificities drives disease progression. For 
example, point mutations to the lysine methyltransferase 
EZH2 that change the product specificity of the PRC2 com-
plex from monomethyl- to trimethyl-lysine have been char-
acterized in a subset of lymphoma patients. As a result, het-
erozygosity leads to the coordinated activities of mutant and 
wild-type enzymes in the trimethylation of lysine 27 on his-
tone H3, a notorious mark that is ubiquitous in many cancers 
[9, 10]. Translocations creating fusion proteins with aberrant 
activity have also been observed in disease, such as the 
MLL-partner fusions that result in the mistargeting of 
H3K79 methylation by DOT1L in childhood leukemias [11] 
or NSD1-nucleoporin 98 fusions that are associated with 
acute myeloid leukemia [12]. Recently, overexpression of 
the lysine methyltransferase SETDB1 was found to acceler-
ate the progression of melanoma in an elegant zebrafish 
model [13], and similarly, overexpression of the lysine 
methyltransferases SMYD3 [14] and G9a [15] have been 
observed in a variety of cancers. In the case of the latter, the 
recent development of selective, sub-nanomolar inhibitors 
[16] will enable its investigation as a target for cancer ther-
apy. In addition, the lysine demethylases LSD1 and 
JARID1B are found to be overexpressed in prostate cancer 
[17], and inhibitors of LSD1 have shown promise in control-
ling the proliferation of cancer cells using xenograft models 
[18]. Ultimately, these examples represent the intersection of 
genetics and epigenetics, and define a targeted patient popu-
lation that will enhance the probability of clinical success. 
  The discovery of potent chemical probes of KMTs and 
KDMs are a critical first step in the dissection of the biologi-
cal pathways they regulate and in understanding the conse-
quences of genetically-driven misregulation of their activi-
ties. These enzymes appear primed for drug discovery, with 
a wealth of structural information now available to guide 
medicinal chemistry efforts, and this is reviewed in this issue 
by articles from Heightman and Shapira. The readers of ly-
sine methylation, including PHD fingers, MBT domains, 
Tudor domains, chromodomains, PWWP repeats and WD40 

















Fig. (2). At least 232 confirmed or putative chromatin-modifying enzymes have been identified. The total number of histone modifying 
enzymes of each class are indicated. This data was compiled using an extensive search of the current literature. The “Other” category in-
cludes ubiquitin ligases, deubiquitinases, SUMO ligases, SUMO isopeptidases and phosphatases. 50    Current Chemical Genomics, 2011, Volume 5  Editorial 
reviewed by Herold et al. The assay technologies that will 
enable chemical exploration of these targets are quickly 
evolving and are highlighted by Quinn and Simeonov and 
Zee et al. Finally, pioneering efforts in HTS and medicinal 
chemistry have indicated that indeed, these enzymes appear 
chemically tractable, and the current state of chemical matter 
targeting histone methylation is reviewed by Yost et al. and 
Heightman in this issue. 
  While it is likely that modulators of histone lysine methy-
lation will yield clinical candidates in the future, the study of 
histone lysine methylation and its effect on biological proc-
esses is still in its relative infancy. It remains to be seen how 
many enzymes or proteins will make for good therapeutic 
targets. The integration of current efforts in genomics, 
chemical biology and drug discovery efforts should begin to 
deliver greater understanding of the potential of epigenetic 
targets. The research undertakings and accomplishments 
reviewed in this issue will be critical in the validation of 
small molecule modulators of methyl-lysine writers, readers 
and erasers as first-in-class molecular targeted therapies. 
These targeted agents should be an improvement over cur-
rent treatments, and will have a profound impact on patients 
with unmet medical needs. 
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